https://doi.org/10.55788/3e92c597
Diabetes is common in people with AD and having diabetes in midlife is a risk factor for being diagnosed with AD later in life [1]. In addition, similar patterns of glucose dysregulation in the brain are observed across the 2 disorders [2]. However, as previous research mainly focused on the relationship between diabetes and clinical AD diagnosis, the question remains whether diabetes is related to underlying AD brain pathology, and whether AD biomarkers and diabetes are synergistically associated with cognitive decline. PhD student Veerle van Gils (Maastricht University, the Netherlands) aimed to answer these questions and analysed clinical data from over 4,000 people with either normal cognition or mild cognitive impairment (MCI) from multiple European memory clinics [3]. Available data included diabetes diagnosis, AD biomarkers (amyloid and tau in liquor), and cognition (at baseline and at least at 1 follow-up).
In people with normal cognition (n=2,678), no correlation was found between diabetes diagnosis or abnormal blood glucose and either abnormal amyloid or tau. In people with MCI (n=1,494), there was a significant correlation between diabetes diagnosis and abnormal levels of amyloid (P=0.04). However, this correlation was the opposite of what was expected, as having a diagnosis of diabetes was a negative predictor for having abnormal amyloid.
As expected, both abnormal amyloid and abnormal tau levels were associated with memory dysfunction at baseline and a decline of memory over time. The AD biomarker levels were also associated with a decline in attention and in executive function over time. Diabetes diagnosis was only associated with attention dysfunction and executive dysfunction at baseline.
Based on these results, Ms van Gils concluded that “there are no synergistic effects of AD biomarkers and diabetes on cognitive functioning and decline. Thus, diabetes and AD affect cognition differently and independently of each other.”
- Chatterjee S, Mudher A. Front Neurosci. 2018;12:383.
- Shieh JC-C, et al. Mol Neurobiol. 2020;57:1966–1977.
- Van Gils V, et al. Insulin signalling and cognitive decline in elderly: a relation to Alzheimer’s disease pathophysiology? Abstract S12.02, ECNP Congress 2022, 15–18 October, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Oxytocin treatment induces long-lasting neurobiological adaptations in autism Next Article
Different brain responses to fat and/or sugar »
« Oxytocin treatment induces long-lasting neurobiological adaptations in autism Next Article
Different brain responses to fat and/or sugar »
Table of Contents: ECNP 2022
Featured articles
Letter from the Editor
New Medications
Zuranolone shows rapid-acting efficacy in postpartum depression
Probiotics could reduce perceived stress
KarXT is effective in schizophrenic patients experiencing acute psychosis
Low-dose ulipristal acetate is an effective treatment for PMDD
New Findings
Endogenous oxytocin release helps the mind to deal with pain
Nitric oxide synthase genetic variant is a risk factor for suicidal behaviour
Early-life gut microbiota depletion changes brain morphology and behaviour
Digital Technology
Treating intrusive memories after trauma in healthcare workers using Tetris
VR exposure as effective as in vivo exposure for phobia
Efficacy of smartphone-based treatment of bipolar disorders not (yet) validated
Psilocybin
Mode of action of psilocybin
Fast and sustained effect of 2 administrations of psilocybin on depression
Antidepressant properties of psilocybin might be related to changes in sleep
Peripartum Neurobiology
Both sex hormones and serotonin play a role in peripartum mental health
Child loss induces short- and long-term neurobiological changes
Reproductive state matters when looking at the female brain and drug treatment effects
Miscellaneous
Different brain responses to fat and/or sugar
Diabetes not related to abnormal biomarkers of Alzheimer’s disease
Oxytocin treatment induces long-lasting neurobiological adaptations in autism
Related Articles

November 26, 2021
Brain Prize Lecture: Prof. Jes Olesen on migraine

November 28, 2022
Letter from the Editor
November 2, 2020
Predicting MCI and dementia by assessing worrying about memory
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com